Latest Communications

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.

12 July 2011
MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners

13 June 2011
APR Applied Pharma Research s.a. and Labtec GmbH announce Ondansetron Oral Dispersible Film (“ODF”) is now available for licensing in Europe and selected non European countries, after having received marketing authorization in most countries of Europe.


The principal elements of our business strategy are:

Develop and licensing our portfolio of product candidates.


We expect to focus a substantial portion of our efforts on the further development, approval and commercialization of our existing portfolio of product candidates.

portfolio of product candidates.

A key element of our partnering strategy is to enter into license agreements with leading corporations to commercialize our product candidates in most of the countries worldwide

Build a product pipeline through innovation, inlicensing and acquisition.


We intend to build our future product pipeline by stimulating internally driven innovation as well as through in-licensing and/or acquisition of select proprietary product candidates and/or new proprietary technology platforms primarily in the oral and topical fields;

Click here to see our Business Model.

Leverage development efforts through strategic Partnerships.


While maintaining overall internal control and management of the planning, execution, development and regulatory processes, we seek to enter into strategic partnerships to boost development of our product candidates: such partnerships include collaborative arrangements with technology, manufacture, and/or know how providers;

Click here to see our current partnership arrangements.

Offer Value Added development Services.


We intend to continue to offer value added development services to pharmaceutical companies under contract and helping them to develop their own product pipeline.

The Company is structured and organized as a centrally managed, vertically Integrated, global product development company and it is positioned as a one stop shop for all R&D and regulatory activities.

We have positioned APR as preferred
General Contractor able to manage, execute and supervise the entire development project on behalf of our clients.




Search results